MS4A1 and cardiac hypertrophy: Relevant studies in the treatment of heart failure have demonstrated that the administration of rituximab, which targets the CD20 receptor on B cells, can ameliorate cardiac hypertrophy and enhance cardiac performance in a murine model subjected to transverse aortic constriction (25).